Source comparison
MOTS-C Nasal vs Injectable: Delivery Method Comparison
Subcutaneous Injection 95%+ 30–45 minutes 3×/week Moderate (requires injection technique, site rotation, sharps disposal) 50–65% Best for acute metabolic timing and users comfortable with self-injection. Bioavailability advantage is real but adherence risk is
This comparison does not assign a generated winner or score.
- Subcutaneous Injection
- 95%+
- 30–45 minutes
- 3×/week
- Moderate (requires injection technique, site rotation, sharps disposal)
- 50–65%
- Best for acute metabolic timing and users comfortable with self-injection. Bioavailability advantage is real but adherence risk is higher
- Intranasal Spray
- 40–60%
- 60–90 minutes
- 1–2×/day
- Low (simple spray administration, no preparation required)
- 80–85%
- Best for long-term metabolic conditioning where consistency outweighs peak concentration. Convenience drives better real-world outcomes
- Oral (Not Viable)
- <5%
- N/A
- Gastric enzymes degrade MOTS-C before systemic absorption. Not a commercially viable route